Synthesis, transport and pharmacokinetics of 5-amino acid ester prodrugs of 1-β-D-arabinofuranosylcytosine

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 315-325

  Sun, Yongbing ^a   Sun, Jin ^a   Shi, Liang ^b   Jing, Yongkui ^a,c   Yin, Shiliang ^a   Chen, Ying ^d   Li, Gang ^a   Xu, Youjun ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Bioavailability; Cytarabine; Hepatic portal vein; Intestinal oligopeptide transporter 1; Pharmacokinetics; Prodrug

Indexed keywords

5' DEXTRO PHENYLALANYLCYTARABINE; 5' DEXTRO VALYLCYTARABINE; 5' ISOLEUCYLCYTARABINE; 5' PHENYLALANYLCYTARABINE; 5' TRYPTOPHYLCYTARABINE; 5' VALYL CYTARABINE; CYTARABINE; CYTARABINE DERIVATIVE; ESTER DERIVATIVE; GLYCYLSARCOSINE; LAMIVUDINE; PEPTIDE TRANSPORTER 1; PRODRUG; UNCLASSIFIED DRUG; AMINO ACID; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ESTERIFICATION; METABOLISM; SYNTHESIS; TEMPERATURE;

AMINO ACIDS; ANIMALS; CACO-2 CELLS; CELL PROLIFERATION; CYTARABINE; ESTERIFICATION; HUMANS; MOLECULAR STRUCTURE; PRODRUGS; RATS; TEMPERATURE;

EID: 62649140994     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800200a     Document Type: Article

References (42)

1. Pallavicini, M. G. Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations. Pharmacol. Ther. 1984, 25 (2), 207-38.
2. Rustum, M.; Raymakers, R. A. 1-Beta-D-arabinofuranosylcytosine in the therapy of leukemia: preclinical and clinical overview. Pharmacol. Ther. 1992, 56 (3), 307-21.
3. Grant, S. Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 1997, 72, 197-233.
4. Furth, J. J.; Cohen, S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-beta-D-arabinofuranosylcytosine and 5′-triphosphate of 9-beta-D-arabinofuranosyladenine. Cancer Res. 1968, 28 (10), 2061-7.
5. Graham, F. L.; Whitmore, G. F. Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosyl-cytosine 5′-triphosphate. Cancer Res. 1970, 30 (11), 2636-44.
6. Major, P. P.; Egan, E. M.; Beardsley, G. P.; Minden, M. D.; Kufe, D. W. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. U.S.A. 1981, 78 (5), 3235-9.
7. Kufe, D. W.; Major, P. P.; Egan, E. M.; Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem. 1980, 255 (19), 8997-9000.
8. Capizzi, R. L.; White, J. C.; Powell, B. L.; Perrino, F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 1991, 28 (1), 54-69.
9. Gray, G. D.; Crim, J. A.; Michelson, M. M. Immunosuppressive activity of ara-cytidine. II. Effects on the graft-versus-host reaction. Transplantation 1968, 6 (7), 818-25.
10. Hadfield, A. F.; Sartorelli, A. C. The pharmacology of prodrugs of 5-flourouracil and 1-β-D-arabinofuranosylcytosine. Adv. Pharmacol. Chemother. 1984, 20 (1), 21-67.
11. Cheon, E. P.; Hong, J. H.; Han, H. K. Enhanced cellular uptake of ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J. Pharm. Pharmcol. 2006, 58 (7), 927-32.
12. Cheon, E. P.; Han, H. K. Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C. Acta Pharmacol. Sin. 2007, 28 (2), 268-72.
13. Gray, G. D.; Nichol, F. R.; Mickelson, M. M.; Camiener, G. W.; Gish, D. T.; Kelly, R. C.; Wechter, W. J.; Moxley, T. E.; Neil, G. L. Immunosuppressive, antiviral and antitumor activities of cytarabine derivatives. Biochem. Pharmacol. 1972, 21 (4), 465-75.
14. Han, H. K.; De Vrueh, R. L.; Rhie, J. K.; Covitz, K. M.; Smith, P. L.; Lee, C. P.; Oh, D.; Sadee, W.; Amidon, G. L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15 (8), 1154-9.
15. Oh, D. M.; Han, H. K.; Amidon, G. L. Drug transport and targeting; Kluwer Academic/Plenum: New York,1999; pp 59-88.
16. Han, H. K.; Amidon, G. L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000, 2 (1), 1-11.
17. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci. 2002, 23 (9), 434-40.
18. Nielsen, C. U.; Brodin, B.; Jorgensen, F. S.; Frokjaer, S.; Steffansen, B. Human peptide transporters: therapeutic applications. Expert Opin. Ther. Pat. 2002, 12 (9), 1329-50.
19. Beauchamp, L. M.; Orr, G. F.; De Miranda, P.; Burnette, T.; Krenitsky, T. A. Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. 1992, 3 (3), 157-64.
20. Beutner, K. R. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 1995, 28 (4), 281-90.
21. Balimane, P. V.; Tamai, I.; Guo, A. L.; Nakanishi, T.; Kitada, H.; Leibach, F. H.; Tsuji, A.; Sinko, P. J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250 (2), 246-51.
22. Bueno, A. B.; Collado, I.; de Dios, A.; Domingguez, C.; Martin, J. A.; Martin, L. M.; Martinez-Grau, M. A.; Montero, C.; Pedregal, C.; Catlow, J.; Coffey, D. S.; Cley, M. P.; Dantzig, A. H.; Lindstrom, T.; Monn, J. A.; Jiang, H. Y.; Schoepp, D. D.; Stratford, R. E.; Tabas, L. B.; Tizaano, J. P.; Wright, R. A.; Herin, M. F. Dipeptides as effective prodrugs of unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a select group II metabotropic glutamate receptor agonist. J. Med. Chem. 2005, 48 (16), 5305-20.
23. Perkins, E. J.; Abraham, T. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S, 2S, 5R, 6S)-2-[(2′S)-(2-amino)propionyl] aminobicyclo[3.1.0.] hexen-2, 6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity. Drug Metab. Dispos. 2007, 35 (10), 1903-9.
24. Wang, F.; Hua, H. M.; Pei, Y. H.; Chen, D.; Jing, Y. K. Triterpenoids from the resin of styrax tonkinensis and their antiproliferative and differentiation effects in human leukemia HL-60 cells. J. Nat. Prod. 2006, 69, 807-10.
25. Gao, J.; Hugger, E. D.; Beck-Westermeyer, M. S.; Borchardt, R. T. Esimating intestinal permeation of compounds using Caco-2 cell monolayers. In Current Protocol in Pharmacology; Enna, S. J., Williams, M., Ferkany, J. W., Kenakin, T., Porsolt, R. D., Sullivan, J. P. Eds.; Wiley: New York, 2000; pp 721-3.
26. Khan, S. I.; Abourashed, E. A.; Khan, I. A.; Walker, L. A. Transport of parthenolide across human intestinal cells (Caco-2). Planta Med. 2003, 69 (5), 1009-12.
27. Khan, S. I.; Abourashed, E. A.; Khan, I. A.; Walker, L. A. Transport of haman alkaloids across Caco-2 cell monolayers. Chem. Pharm. Bull. 2004, 52 (4), 394-7.
28. Konishi, Y.; Hagiwara, K.; Shimizu, M. Transepithelial transport of fluorescein in Caco-2 cell monolayers and use of such transport in invitro evaluation of phenolic acid availability. Biosci. Bio- technol. Biochem. 2002, 66 (11), 2449-57.
29. Sakai, M.; Imai, T.; Ohtake, H.; Azuma, H.; Otagiri, M. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J. Pharm. Sci. 1997, 86 (7), 779-85.
30. Terada, T.; Saito, H.; Mukai, M.; Inui, K. Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am. J. Physiol. 1997, 273 (5), F706-11.
31. +-coupled peptide cotransporter 1 activity and expression in vivo: evidence in leptin-deficient mice. J. Pharmacol. Exp. Ther. 2007, 323 (1), 192-201.
32. Nduati, V.; Yan, Y. T.; Dalmasso, G.; Driss, A.; Sitaraman, S.; Merlin, D. Leptin transcriptionally enhances peptide transporter (hPepT1) expression and activity via Camp-response element-bingind pritein Cdx2 transportion factors. J. Biol. Chem. 2007, 282 (2), 1359-73.
33. Lorenzi, P. L.; Landowski, C. P.; Song, X. Q.; Borysko, K. Z.; Breitenbach, J. M.; Kim, J. S.; Hilfinger, J. M.; Townsend, L. B.; Darch, J. C.; Amidon, G. L. Amino acid ester prodrugs of 2-Bromo-5,6-dichloro-1-(β-D- ribofuranosyl) benzimidazole enhance metabolic stability in vitro and in vivo. J. Pharmacol. Exp. Ther. 2005, 314 (2), 883-90.
34. Sun, Y. B.; Sun, J.; Wen, B.; Shi, S. L.; Xu, Y. J.; Chen, Y.; Wang, Y. J.; Pan, C. Q.; Zhang, C. Y.; Zhang, T. H.; He, Z. G. High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma. J. Chromatogr. B. 2008, 870 (1), 121-5.
35. Landowski, C. P.; Song, X. Q.; Lorenzi, P. L.; Hilfinger, J. M.; Amidon, G. L. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm. Res. 2005, 22 (9), 1510-8.
36. Song, X. Q.; Lorenzi, P. L.; Landowski, C. P.; Vig, B. S.; Hilfinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharmaceutics 2005, 2 (2), 157-67.
37. Song, X. Q.; Vig, B. S.; Lorenzi, P. L.; Darch, J. C.; Townsend, L. B.; Amidon, G. L. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole as potential substrates of hPEPT1 transporter. J. Med. Chem. 2005, 48 (4), 1274-7.
38. Chen, Z.; Fei, Y. J.; Anderson, C. M. H.; Wake, K. A.; Miyauchi, S.; Huang, W.; Thwaites, D. T.; Ganapathy, V. Structure, function, and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J. Physiol. 2003, 546 (2), 349-61.
39. Granero, G. E.; Amino, G. L. Stability of valacyclovir: implication for its oral bioavailability. Int. J. Pharm. 2006, 317 (1), 14-8.
40. Wan, S. H.; Huffman, D. H.; Azarnoff, D. L.; Hoogstraten, B.; Larsen, W. Pharmacokinetics of1-beta-D-arabinofuranosylcytosine in humans. Cancer Res. 1974, 34 (2), 392-7.
41. Tsume, Y.; Hilfinger, J.; Amino, G. L. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol. Pharmaceutics 2008, 5 (5), 717-27.
42. Li, F. J.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 2008, 97 (3), 1109-34.